Sanara MedTech (SMTI) Projected to Post Earnings on Wednesday

Sanara MedTech (NASDAQ:SMTI - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $23.48 million for the quarter.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. The company had revenue of $26.31 million during the quarter, compared to the consensus estimate of $22.75 million. On average, analysts expect Sanara MedTech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sanara MedTech Stock Up 4.4%

Sanara MedTech stock traded up $1.42 during midday trading on Monday, hitting $33.77. 50,805 shares of the stock were exchanged, compared to its average volume of 25,913. The company has a 50 day moving average price of $31.03 and a two-hundred day moving average price of $33.45. The firm has a market cap of $300.11 million, a P/E ratio of -34.11 and a beta of 1.38. Sanara MedTech has a 1 year low of $25.86 and a 1 year high of $39.08. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.23 and a quick ratio of 2.02.

Analyst Ratings Changes

SMTI has been the subject of a number of recent research reports. HC Wainwright boosted their price objective on shares of Sanara MedTech from $50.00 to $51.00 and gave the company a "buy" rating in a research report on Wednesday, March 26th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $46.00 price target on shares of Sanara MedTech in a research note on Wednesday, March 26th.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.